| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8367657 | EISAI INC | Processes for preparing 3-benzazepines |
Apr, 2023
(1 year, 23 days ago) | |
| US7977329 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 23 days ago) | |
| US8546379 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 23 days ago) | |
| US6953787 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 23 days ago) | |
| US8697686 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 7 months from now) | |
| US8168624 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Apr, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8273734 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 23 days ago) | |
| US8207158 | EISAI INC | 5HT2c receptor modulators |
Apr, 2023
(1 year, 23 days ago) | |
| US8575149 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 23 days ago) | |
| US7514422 | EISAI INC | 5HT2c receptor modulators |
Apr, 2023
(1 year, 23 days ago) | |
| US8946207 | EISAI INC | Processes for preparing 3-benzazepines |
Jun, 2024
(a month from now) | |
| US8980881 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 7 months from now) | |
| US10463676 | EISAI INC | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
Aug, 2031
(7 years from now) | |
| US10226471 | EISAI INC | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
Aug, 2031
(7 years from now) | |
| US9770455 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Aug, 2031
(7 years from now) | |
| US9169213 | EISAI INC | Method of weight management |
Dec, 2032
(8 years from now) | |
| US8999970 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Feb, 2033
(8 years from now) | |
Belviq Xr is owned by Eisai Inc.
Belviq Xr contains Lorcaserin Hydrochloride.
Belviq Xr has a total of 17 drug patents out of which 8 drug patents have expired.
Expired drug patents of Belviq Xr are:
- US8273734
- US8207158
- US8575149
- US7514422
- US8367657
- US7977329
- US8546379
- US6953787
Belviq Xr was authorised for market use on 15 July, 2016.
Belviq Xr is available in tablet, extended release;oral dosage forms.
Belviq Xr can be used as method for chronic weight management in patients with moderate renal impairment who are obese, or overweight and have at least one weight related comorbid condition, method for chronic weight management by decreasing food intake, method for chronic weight management by treating obesity, method for chronic weight management by controlling weight gain, method for chronic weight management by treating obesity in an individual who does not have severe renal impairment or esrd, use of lorcaserin hydrochloride for chronic weight management by treating obesity in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment, chronic weight management in adult patients using an extended release tablet containing lorcarserin hydrochloride hemihydrate, method for chronic weight management.
Drug patent challenges can be filed against Belviq Xr from 27 June, 2016.
The generics of Belviq Xr are possible to be released after 07 February, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 15 July, 2016
Treatment: Method for chronic weight management by controlling weight gain; Method for chronic weight management; Method for chronic weight management by treating obesity; Chronic weight management in adult pati...
Dosage: TABLET, EXTENDED RELEASE;ORAL
BELVIQ XR family patents
